Photodynamic therapy (PDT) using nanobodies targeting human epidermal growth factor receptor 2 (HER2) is a promising treatment for a significant number of breast cancer patients with residual disease after neoadjuvant or trastuzumab resistance. This evidence concerns the gene ERBB2 and breast carcinoma.